You are here

Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DK119048-01
Agency Tracking Number: R41DK119048
Amount: $225,072.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIDDK
Solicitation Number: PA17-303
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-08-20
Award End Date (Contract End Date): 2019-08-19
Small Business Information
154 NW MAYWOOD DR
Portland, OR 97210-3330
United States
DUNS: 080341719
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 PETER GALEN
 (503) 554-4222
 galen@panmed.com
Business Contact
 PATTI WHITE
Phone: (503) 703-7696
Email: p.white@hemexhealth.com
Research Institution
 CASE WESTERN RESERVE UNIVERSITY
 
10900 EUCLID AVE
CLEVELAND, OH 44106-1712
United States

 Nonprofit College or University
Abstract

PROJECT SUMMARY
Diabetes is one of the most important health issues in the worldIt is a disease that disproportionately affects
low and middle income countriesNot only is diabetes a major cause of morbidity and mortalityit can devastate
the finances of families and strain countriesfinancial resourcesKey components for addressing this healthcare
crises include early diagnosis as well as ongoing monitoring of the conditionAccess to testinghowevercan be
limited in many developing countries due to the lack of skilled healthcare workers as well as costTo address
this needHemex Health is developing an accuratelow costeasy to use hemoglobin A C test that can be
administered by an entry level healthcare worker after a short trainingThe test is based on our proprietary
HemeChip technology known as microchip electrophoresisThe current form of the HemeChip assay accurately
identifies and quantifies hemoglobin variantsand is currently in the process of commercialization with a focus
on hemoglobinopathiesincluding sickle cell disease and thalassemiaThe proposed project aims to translate
the cellulose acetate based A C electrophoresis method to the HemeChip platform as a portableaffordableand quantitative testFor many yearsthe A C testwhich measures glucose control over a period of monthshas become an important tool in wealthier countries for managing diabetesIt is also more convenient than
glucose tests that require fastingThe Hemex devicebecause of its ease of useportabilityand affordabilitycan bring A C testing to where the need is the greatestIt will offer millions of people an easy and affordable
screening device and for diabetics the opportunity for regular monitoring in order to better control their disease PROJECT NARRATIVE
Diabetes is a disease that disproportionately affects low and middle income countriesEffective
management of diabetes should include early diagnosis and ongoing monitoring of the conditionbut access to testing can be limited in many developing countries due to the lack of skilled
healthcare workers as well as costTo address this needHemex Health is proposing to develop
an accuratelow costeasy to use A C test that can be administered by an entry level healthcare
worker after a short training

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government